Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Pipeline Review, H2 2016

  • ID: 3961150
  • Report
  • 77 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Aptevo Therapeutics Inc
  • ARMO Biosciences, Inc.
  • BioMAS Ltd.
  • Biotest AG
  • enGene, Inc
  • Intrexon Corporation
  • MORE
Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Pipeline Review, H2 2016

‘Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics development and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
- Certain sections in the report may be removed or altered based on the availability and relevance of data.
- Updated report will be delivered in 48 hours of order confirmation.

Scope:

- The report provides a snapshot of the global therapeutic landscape for Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)
- The report reviews Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics

Reasons to Buy:

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aptevo Therapeutics Inc
  • ARMO Biosciences, Inc.
  • BioMAS Ltd.
  • Biotest AG
  • enGene, Inc
  • Intrexon Corporation
  • MORE
Introduction

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) Overview

Therapeutics Development

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Stage of Development

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Therapy Area

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Indication

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Companies

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Products under Development by Universities/Institutes

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Companies Involved in Therapeutics Development

Aptevo Therapeutics Inc

ARMO Biosciences, Inc.

BioMAS Ltd.

Biotest AG

enGene, Inc

Intrexon Corporation

LEO Pharma A/S

Merck & Co., Inc.

P2D Bioscience

Pfizer Inc.

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Drug Profiles

AM-0010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANV-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic to Activate Glutamic Acid Decarboxylase and IL-10 for Type 1 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic to Target Insulin Receptor and IL-10 for Type 1 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BT-063 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CB-0602 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTLA-4 X mono-IL-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Dekavil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EG-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EG-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Elmyelin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Interleukin 10 for Atherosclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Interleukin-10 for ALS - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LEO-32731 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-1966 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-2244 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit IL-10 and IFN Gamma for Cancer, Viral Infections and Inflammatory Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XT-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XT-150 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Dormant Projects

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Discontinued Products

Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) - Featured News & Press Releases

Sep 26, 2016: ARMO BioSciences Announces Data Presentations at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

Aug 15, 2016: ARMO BioSciences Announces Publication of AM0010 Clinical Data in Advanced Solid Tumor Patients in Journal of Clinical Oncology

Jun 06, 2016: ARMO BioSciences AM0010 Demonstrates Promising Clinical Data as an Immuno-oncology Monotherapy and in Combination with an Anti-PD-1 Checkpoint Inhibitor in Advanced Solid Tumors, Including Immune-Resistant Cancers

Apr 20, 2016: ARMO BioSciences Announces AM0010 Clinical Data to be Presented at the American Society of Clinical Oncology Annual Meeting in June 2016

Mar 31, 2016: Xalud Therapeutics Discovers Potential Solution for Opioid Abuse Crisis

Mar 16, 2016: ARMO BioSciences to Present New Clinical Trial Results for AM0010 at Upcoming Medical Conferences

Jan 08, 2016: ARMO BioSciences to Present at the 34th Annual J.P. Morgan HealthCare Conference

Oct 30, 2015: ARMO BioSciences Presents Positive Phase 1 Trial Results of AM0010 at Upcoming Medical Conferences

Oct 06, 2015: Biotest reaches the next milestone in the clinical development of its monoclonal antibody BT-063 by starting the clinical phase IIa trial in the indication systemic lupus erythematosus

Jun 01, 2015: ARMO BioSciences Announces Efficacy and Safety Data for Immuno-Oncology Program with Novel Mechanism of Action

May 13, 2015: ARMO BioSciences Announces Presentation on Promising Immuno-Oncology Program at 2015 ASCO Annual Meeting

Jun 23, 2014: Cytovance Biologics selected for GMP manufacture of AM0010 for ARMO BioSciences

Nov 25, 2013: ARMO BioSciences Initiates Phase 1 Clinical Trial of First-In-Class Cancer Immunotherapy

Apr 11, 2012: University Of Leuven And ActoGeniX Announce Study Results Of ActoBiotic In Treatment Of Type 1 Diabetes

Sep 30, 2009: Biotest AG Announces Initiation of Clinical development of BT-063

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by Aptevo Therapeutics Inc, H2 2016

Pipeline by ARMO Biosciences, Inc., H2 2016

Pipeline by BioMAS Ltd., H2 2016

Pipeline by Biotest AG, H2 2016

Pipeline by enGene, Inc, H2 2016

Pipeline by Intrexon Corporation, H2 2016

Pipeline by LEO Pharma A/S, H2 2016

Pipeline by Merck & Co., Inc., H2 2016

Pipeline by P2D Bioscience, H2 2016

Pipeline by Pfizer Inc., H2 2016

Dormant Projects, H2 2016

Dormant Projects (Contd..1), H2 2016

Dormant Projects (Contd..2), H2 2016

Discontinued Products, H2 2016

List of Figures

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Top 10 Indication, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Type, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aptevo Therapeutics Inc
  • ARMO Biosciences, Inc.
  • BioMAS Ltd.
  • Biotest AG
  • enGene, Inc
  • Intrexon Corporation
  • LEO Pharma A/S
  • Merck & Co., Inc.
  • P2D Bioscience
  • Pfizer Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll